GBA VIR TARGET: $150!!!!!!! NOV 30. We Covered This At The Time- That's why folks read GBA! Vir Biotechnology price target raised to $200 from $135 at H.C. Wainwright 11/30 VIR, GSK H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Vir Biotechnology (VIR) to $200 from $135 and reiterates a Buy rating on the shares. The analyst expects a "robust" COVID-19 antiviral market, with Vir as a leader. Several recent updates suggest that Vir and its collaboration partner GlaxoSmithKline (GSK) are likely to maintain a top-tier COVID-19 antiviral franchise, led at first by sotrovimab, "for the foreseeable future," Trucchio tells investors in a research note. He believes that as investors better appreciate the potential for a robust prophylaxis mAb market, potentially larger post-infection antiviral market as more SARS-CoV-2 variants emerge, and the differentiated approach by Vir and GSK, Vir shares "should increase substantially."
Santa Needs A Rally - Let's Give Him One - Fed could say Growing Omicrom menace has to be watched pushing out rate hikes further.
MTTR- Tempted to plant this. Matterport, Inc. (MTTR)- what is down side $17?// Upside $42 NasdaqGM - NasdaqGM Real Time Price. Currency in USD 21.56-0.74 (-3.32%)
... We have to be careful because the changing environment for stocks. pricey tech is out i have to keep telling myself as I gravitate there. However Mattaport I don't really see that way.